Project Farma is an industry leader in providing project management, validation, engineering and consulting services with a proven track record in gene and cell therapy. We partner with cell and gene therapy organizations in addition to healthcare, pharmaceutical, bio-pharmaceutical companies to support finding ground-breaking treatments and solutions. Our clients include startups, small and large pharmaceutical and biotech companies and CMOs/CROs. We are committed to helping advance cutting-edge medicines by leveraging our deep knowledge and broad experience in cell and gene therapy to meet any new challenges. With over 200 employees, our business infrastructure enables robust scalability to ensure that the proper resources are available to support the project.
PPD® Biotech is devoted to finding the right Phase I-IV clinical development solutions for biotech and small to midsize pharma. With dedicated teams, PPD Biotech combines the global resource scalability and full-service offerings of PPD with personal attention, flexibility and a shared mindset that enables us to find the optimal solutions for your study, no matter the size.
BIA Separations has 20 years’ experience in chromatographic purification. Our products, CIM monoliths, were designed with unique operating properties that make them ideally suited to the challenging requirements of purifying biomolecules such as virus particles, vesicles, proteins, RNA’s, plasmids and other forms of DNA. We provide products that range from small analytical columns to large industrial prep-scale columns (including cGMP and disposable units) as well as method development services.
Brammer Bio is dedicated to providing clinical and commercial viral vectors for in vivo gene and ex vivo gene-modified cell therapies, from process and analytical development through commercial approval. We have a highly skilled team of scientists with expertise from over 100 client projects to tackle the challenges posed by these novel technologies and help accelerate their transition from the clinic to patients, while focusing on meeting cGMP standards. Brammer Bio is Helping to Cure.®
QPS is a global, science driven, customer-focused CRO that provides preclinical studies and clinical trials to the biotech and pharmaceutical industries. Our 1100+ person organization has expertise in nearly all drug modalities including small molecules, proteins, and other biotherapeutics. We have supported gene therapy since 2002: ASOs, siRNAs, miRNA through mRNAs and viral vectors. Our bioanalytical technologies include LC-HRMS, hybridization-LC, and qPCR; while our full spectrum DMPK services covers PK, DDI, biodistribution, and radiolabel studies.
Your bioanalytical CRO Partner for biologic drug development (Preclinical, Clinical and GMP tests).
GenoSafe is a CRO providing the laboratory analytical testing under GLP, GMP and GCP compliance. Its scientific fields of expertise are biomolecular, virology, and immunology. With half of its activities in the US and the rest in Europe, GenoSafe has a unique knowhow for advanced therapeutic medical products development and evaluation. GenoSafe's clients are biotech, pharmaceuticals, public/private research laboratories and Universities/Hospitals.
Trinity is a trusted strategic advisor providing evidence-based commercial solutions for clients in the life sciences industry. With over 20 years of experience, TRINITY is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. The team at our flagship European office in Munich has extensive experience supporting clients in both gene therapy and rare diseases on their commercialization strategy, go-to-market model, and key strategic market access topics.
Passage Bio is a privately-held genetic medicines company with a mission to develop a portfolio of life-transforming AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program and the Orphan Disease Center. The companies lead programs are in Krabbe Disease, Type 1 GM1 Gangliosidosis and Frontotemporal Dementia.